Lupin Pharmaceuticals Famotidine for Oral Suspension Recall

Why it was recalled

CGMP Deviations

Product description

Famotidine for Oral Suspension USP, 40 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA, NDC 68180-150-01

Lot numbers, UPCs & expiration codes

Lot #: G606950, Exp 07/18

Where it was sold

Nationwide in the USA

What to do if you have this product

Compare the lot number and expiration date on your package with the codes above.
Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
If you have symptoms you think are related, contact your doctor. In an emergency call 911.
Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number: D-1127-2017
Classification: Class III
Status: Terminated
Recall initiated: May 2, 2017
FDA report date: Sep 13, 2017
Quantity: 12,888 bottles
Recall type: Voluntary: Firm initiated
Recalling firm: Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-1127-2017, exactly as published.

Show all FDA fields

City: Baltimore
State: MD
Status: Terminated
Country: United States
Event ID: 78032
Address: 111 S Calvert St Fl 21ST
Code information: Lot #: G606950, Exp 07/18
Postal code: 21202-6174
Report date: Sep 13, 2017
Product type: Drugs
Recall number: D-1127-2017
Classification: Class III
Recalling firm: Lupin Pharmaceuticals Inc.
Product quantity: 12,888 bottles
Termination date: Mar 28, 2018
Reason for recall: CGMP Deviations
Voluntary / mandated: Voluntary: Firm initiated
Product description: Famotidine for Oral Suspension USP, 40 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA, NDC 68180-150-01
Distribution pattern: Nationwide in the USA
Recall initiation date: May 2, 2017
Initial firm notification: E-Mail
Center classification date: Sep 1, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1127-2017, published Sep 13, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: Oct 2, 2026. Content last changed: Oct 2, 2026.

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.